Guardion Health Sciences, Inc. (NASDAQ:GHSI) Sees Large Growth in Short Interest

Guardion Health Sciences, Inc. (NASDAQ:GHSI) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 139,800 shares, an increase of 14.2% from the March 15th total of 122,400 shares. Approximately 13.7% of the shares of the company are short sold. Based on an average daily trading volume, of 208,600 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “hold” rating on shares of Guardion Health Sciences in a research report on Friday, February 2nd.

Hedge Funds Weigh In On Guardion Health Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. bought a new stake in Guardion Health Sciences during the third quarter worth approximately $110,000. Renaissance Technologies LLC raised its holdings in Guardion Health Sciences by 6.2% during the second quarter. Renaissance Technologies LLC now owns 37,620 shares of the company’s stock worth $293,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Guardion Health Sciences during the second quarter worth approximately $53,000. 20.21% of the stock is currently owned by institutional investors and hedge funds.

Guardion Health Sciences Price Performance

Shares of NASDAQ GHSI traded down $0.04 during midday trading on Tuesday, hitting $7.85. 3,284 shares of the company’s stock were exchanged, compared to its average volume of 189,482. The stock’s 50 day moving average price is $8.41 and its 200-day moving average price is $6.86. The firm has a market cap of $10.05 million, a P/E ratio of 71.37 and a beta of 0.87. Guardion Health Sciences has a twelve month low of $5.01 and a twelve month high of $10.75.

About Guardion Health Sciences

Guardion Health Sciences, Inc, a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.